These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24408661)

  • 1. Initiating levodopa therapy for Parkinson's disease.
    Olanow CW; Kieburtz K; Stocchi F
    Mov Disord; 2014 Mar; 29(3):430. PubMed ID: 24408661
    [No Abstract]   [Full Text] [Related]  

  • 2. Factors predictive of the development of levodopa-induced dyskinesia and Wearing-Off in Parkinson's disease.
    Rajput AH
    Mov Disord; 2014 Mar; 29(3):429. PubMed ID: 24375668
    [No Abstract]   [Full Text] [Related]  

  • 3. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG
    Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract]   [Full Text] [Related]  

  • 4. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 5. Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):198-200. PubMed ID: 29186084
    [No Abstract]   [Full Text] [Related]  

  • 6. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Chaudhuri KR; Jenner P; Antonini A
    Mov Disord; 2019 Jun; 34(6):816-819. PubMed ID: 30983023
    [No Abstract]   [Full Text] [Related]  

  • 7. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy.
    Kim JM; Lee KH; Choi YL; Choe GY; Jeon BS
    Mov Disord; 2002 Sep; 17(5):1089-90. PubMed ID: 12360566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson's Disease.
    Blankenburg H; Falla M; Schwienbacher C; Fabbrini G; Berardelli A; Pramstaller PP; Domingues FS
    Neuroinformatics; 2017 Jul; 15(3):297-300. PubMed ID: 28417316
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ropinirole as compared with levodopa in Parkinson's disease.
    Weiner WJ; Factor SA
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001687
    [No Abstract]   [Full Text] [Related]  

  • 12. Ropinirole as compared with levodopa in Parkinson's disease.
    Frucht S
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001686
    [No Abstract]   [Full Text] [Related]  

  • 13. Ropinirole as compared with levodopa in Parkinson's disease.
    Yamamoto T
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001685
    [No Abstract]   [Full Text] [Related]  

  • 14. Ropinirole as compared with levodopa in Parkinson's disease.
    Hiner BC; Earnhart M
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
    [No Abstract]   [Full Text] [Related]  

  • 15. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 16. A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
    Nutt J
    Mov Disord; 1999; 14 Suppl 1():74. PubMed ID: 10493408
    [No Abstract]   [Full Text] [Related]  

  • 17. Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study.
    Nicoletti A; Zappia M;
    Mov Disord; 2015 Nov; 30(13):1854-6. PubMed ID: 26769461
    [No Abstract]   [Full Text] [Related]  

  • 18. Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease.
    Prashantha DK; Pal PK
    Parkinsonism Relat Disord; 2009 Nov; 15(9):718-9. PubMed ID: 19157953
    [No Abstract]   [Full Text] [Related]  

  • 19. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 20. [Motor and mental complications in the long-term treatment of complicated Parkinson's disease with levodopa].
    Molina JA; Jiménez-Jiménez FJ; Ortí-Pareja M
    Rev Neurol; 1999 May 16-31; 28(10):982-90. PubMed ID: 10416237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.